EdiGene - About the company
EdiGene is a series B company based in Changping District (China), founded in 2015. It operates as a Developer of genome editing technology for the treatment of cancer and genetic disease. EdiGene has raised $165M in funding from investors like Lilly Asia Ventures, IDG Capital and WI Harper Group. The company has 2081 active competitors, including 497 funded and 332 that have exited. Its top competitors include companies like Beam Therapeutics, Antheia and Transcenta.
Company Details
Developer of genome editing technology for the treatment of cancer and genetic disease. The company has developed LEAPER technology, which is an in vivo oligonucleotide-based RNA single-base editing technology used for the treatment of Hurler syndrome. The company's in vitro therapy includes ET-01 for β-thalassemia major and the allogeneic CAR-T ET-02 for cancer.
- Website
- edigene.com
- Social
- Email ID
- *****@edigene.com
- Phone Number
- +86 **********
Key Metrics
Founded Year
2015
Location
Changping District, China
Stage
Series B
Total Funding
$165M in 6 rounds
Latest Funding Round
Investors
Ranked
41st among 2081 active competitors
Employee Count
51 - 200 as on Jul 01, 2024
Similar Companies
Sign up to download EdiGene's company profile
EdiGene's funding and investors
EdiGene has raised a total funding of $165M over 6 rounds. Its latest funding round was a Series B round on Apr 21, 2021 for $*****. 10 investors participated in its latest round. EdiGene has 18 institutional investors.
Here is the list of recent funding rounds of EdiGene:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Apr 21, 2021 | 9657845 | Series B | 3897893 | 5201702 | 6467464 | 7040336 |
Oct 13, 2020 | 5054676 | Series B | 4823678 | 5629853 | 9974367 | |
Sep 16, 2019 | 1127910 | Series A | 5538658 | 7877588 | 9758491 |
Access funding benchmarks and valuations. Sign up today!View details of EdiGene's funding rounds and investors
EdiGene's founders and board of directors
Founder? Claim ProfileEdiGene's employee count trend
EdiGene has 51 - 200 employees as of Jul 24. Here is EdiGene's employee count trend over the years:
Uncover EdiGene's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
EdiGene's Competitors and alternates
Top competitors of EdiGene include Beam Therapeutics, Antheia and Transcenta. Here is the list of Top 10 competitors of EdiGene, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Beam Therapeutics 2017, Cambridge (United States), Public | Developer of gene therapy using CRISPR base editing to treat diseases | $222M | 70/100 | |
2nd | Antheia 2013, Palo Alto (United States), Series C | Genetically engineered yeast cells to produce medicinal products | $176M | 67/100 | |
3rd | Transcenta 2019, Suzhou (China), Public | Developer of antibody-based therapeutics | $205M | 66/100 | |
4th | eGenesis 2015, Cambridge (United States), Series D | Developer of a gene transplantation platform for humanizing pig cells | $495M | 65/100 | |
5th | Developer of antibody drug conjugates for the treatment of broad spectrum diseases | $195M | 65/100 | ||
6th |  Mammoth 2017, Brisbane (United States), Series D | Provider of molecular diagnostics platform by using CRISPR technology | $271M | 65/100 | |
7th |  Scribe Therapeutics 2018, Alameda (United States), Public | Developer of a gene-editing platform using CRISPR technology | $120M | 65/100 | |
8th | Metagenomi 2016, Berkeley (United States), Public | Digital gene editing technologies for drug development | $376M | 64/100 | |
9th | Locus Biosciences 2015, Raleigh (United States), Series B | Developer of therapeutics for infectious disease and inflammatory indications | $67.3M | 64/100 | |
10th | Korro Bio 2018, Cambridge (United States), Public | Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases | $4M | 64/100 | |
41st | Developer of genome editing technology for the treatment of cancer and genetic disease | $165M | 55/100 |
_1523881431192.png?devicePixelRatio=2&height=30&width=30){kind=logo}
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on EdiGene's competitors? Click here to see the top ones
EdiGene's Investments and acquisitions
EdiGene has made no investments or acquisitions yet.
Reports related to EdiGene
Here is the latest report on EdiGene's sector:
News related to EdiGene
Filter this listMedia has covered EdiGene for 1 event in last 1 year.
•
China National Pharmaceutical Group plans to acquire EdiGene for 1.654 billion yuanCnstock•Jun 06, 2026•Sinopharm, EdiGene
•
Researchers Develop "Off-the-Shelf" CAR T-Cell TherapyTechnology Networks•Sep 09, 2025•Peking University, EdiGene
•
•
•
•
•
China medical investor Alwin Capital closes fund at $300mNihon Keizai Shimbun•Oct 28, 2022•Alwyn Capital, Neukio Biotherapeutics, Xbiome, EdiGene and 1 other
•
•
EdiGene and Neukio Enter Collaboration to Develop Next-Generation Immune Cell TherapiesBusiness Wire•Feb 09, 2022•EdiGene, Neukio Biotherapeutics
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about EdiGene
Explore our recently published companies
- Magic Vacations - United States based, Unfunded company
- Pinestar Technology - United States based, Unfunded company
- 225 Cinema - Unfunded company
- bluelemon - France based, 2020 founded, Unfunded company
- Buzzodo - Unfunded company
- Social Consulting - Greece based, Unfunded company
